This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fyles, A. Articles by Hill, R. P. Search for Related Content PubMed PubMed Citation Articles by Fyles, A. Articles by Hill, R. P. Social Bookmarking                            What's this?

Tumor Hypoxia Has Independent Predictor Impact Only in Patients With Node-Negative Cervix Cancer

From the Departments of Radiation Oncology, Medicine, Biostatistics, Clinical Informatics, and Experimental Therapeutics, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network and University of Toronto, Toronto, Canada.

Address reprint requests to Anthony Fyles, MD, Department of Radiation Oncology, Rm 5-984, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada M5G 2M9; email: anthony.fyles{at}rmp.uhn.on.ca

PURPOSE: This prospective clinical study was begun in 1994 to validate the independent prognostic impact of tumor hypoxia in patients with cervix cancer treated with definitive radiation therapy.

PATIENTS AND METHODS: Between May 1994 and January 1999, 106 eligible patients with epithelial cervix cancer had tumor oxygen pressure (PO₂) measured using the Eppendorf probe. Oxygenation data are presented as the hypoxic proportion, defined as the percentage of PO₂ readings less than 5 mm/Hg (abbreviated as HP₅) and the median PO₂.

RESULTS: The median HP₅ in individual patients was 48%, and the median PO₂ was HP₅. Progression-free survival (PFS) for patients with hypoxic tumors (HP₅ > 50%) was 37% at 3 years versus 67% in those patients with better oxygenated tumors (P = .004). In multivariate analysis, only tumor size (risk ratio [RR], 1.33; P = .0003) and evidence of pelvic nodal metastases on imaging studies (RR, 2.52; P = .0065) were predictive of PFS. However, an interaction between nodal status and oxygenation was observed (P = .006), and further analysis indicated that HP₅ was an independent predictor of outcome in patients with negative nodes on imaging (P = .007). There was a significant increase in the 3-year cumulative incidence of distant metastases in the hypoxic group (41% v 15% in those with HP₅ < 50%; P = .0023), but not in pelvic relapse (37% v 27%; P = .12).

CONCLUSION: Tumor hypoxia is an independent predictor of poor PFS only in patients with node-negative cervix cancer, in addition to tumor size. Its impact appears to be related to an increased risk of distant metastases rather than to an effect on pelvic control.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. R. Wilson, S. M. Stribbling, F. B. Pruijn, S. P. Syddall, A. V. Patterson, H.D. S. Liyanage, E. Smith, K. J. Botting, and M. Tercel Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators Mol. Cancer Ther., October 1, 2009; 8(10): 2903 - 2913. [Abstract] [Full Text] [PDF]

				Q.-T. X. Le, J. Moon, M. Redman, S. K. Williamson, P. N. Lara Jr, Z. Goldberg, L. E. Gaspar, J. J. Crowley, D. F. Moore Jr, and D. R. Gandara Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: SWOG 0222 J. Clin. Oncol., June 20, 2009; 27(18): 3014 - 3019. [Abstract] [Full Text] [PDF]

				M. Fiegl, I. Samudio, K. Clise-Dwyer, J. K. Burks, Z. Mnjoyan, and M. Andreeff CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure Blood, February 12, 2009; 113(7): 1504 - 1512. [Abstract] [Full Text] [PDF]

				O. Tredan, A. B. Garbens, A. S. Lalani, and I. F. Tannock The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone Cancer Res., February 1, 2009; 69(3): 940 - 947. [Abstract] [Full Text] [PDF]

				F. He, X. Deng, B. Wen, Y. Liu, X. Sun, L. Xing, A. Minami, Y. Huang, Q. Chen, P. B. Zanzonico, et al. Noninvasive Molecular Imaging of Hypoxia in Human Xenografts: Comparing Hypoxia-Induced Gene Expression with Endogenous and Exogenous Hypoxia Markers Cancer Res., October 15, 2008; 68(20): 8597 - 8606. [Abstract] [Full Text] [PDF]

				C. C. Riedl, P. Brader, P. B. Zanzonico, Y. S. Chun, Y. Woo, P. Singh, S. Carlin, B. Wen, C. C. Ling, H. Hricak, et al. Imaging Hypoxia in Orthotopic Rat Liver Tumors with Iodine 124-labeled Iodoazomycin Galactopyranoside PET Radiology, August 1, 2008; 248(2): 561 - 570. [Abstract] [Full Text] [PDF]

				L. I. Cardenas-Navia, D. Mace, R. A. Richardson, D. F. Wilson, S. Shan, and M. W. Dewhirst The Pervasive Presence of Fluctuating Oxygenation in Tumors Cancer Res., July 15, 2008; 68(14): 5812 - 5819. [Abstract] [Full Text] [PDF]

				F. Dehdashti, P. W. Grigsby, J. S. Lewis, R. Laforest, B. A. Siegel, and M. J. Welch Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone) J. Nucl. Med., February 1, 2008; 49(2): 201 - 205. [Abstract] [Full Text] [PDF]

				P. Brader, C. C. Riedl, Y. Woo, V. Ponomarev, P. Zanzonico, B. Wen, S. Cai, H. Hricak, Y. Fong, R. Blasberg, et al. Imaging of hypoxia-driven gene expression in an orthotopic liver tumor model Mol. Cancer Ther., November 1, 2007; 6(11): 2900 - 2908. [Abstract] [Full Text] [PDF]

				O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock Drug Resistance and the Solid Tumor Microenvironment J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454. [Abstract] [Full Text] [PDF]

				A. Wouters, B. Pauwels, F. Lardon, and J. B. Vermorken Review: Implications of In Vitro Research on the Effect of Radiotherapy and Chemotherapy Under Hypoxic Conditions Oncologist, June 1, 2007; 12(6): 690 - 712. [Abstract] [Full Text] [PDF]

				R. A. Cairns, I. Papandreou, P. D. Sutphin, and N. C. Denko Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy PNAS, May 29, 2007; 104(22): 9445 - 9450. [Abstract] [Full Text] [PDF]

				B. Bachtiary, P. C. Boutros, M. Pintilie, W. Shi, C. Bastianutto, J.-H. Li, J. Schwock, W. Zhang, L. Z. Penn, I. Jurisica, et al. Gene Expression Profiling in Cervical Cancer: An Exploration of Intratumor Heterogeneity. Clin. Cancer Res., October 1, 2006; 12(19): 5632 - 5640. [Abstract] [Full Text] [PDF]

				H. Chen, Y. Yan, T. L. Davidson, Y. Shinkai, and M. Costa Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone Methyltransferase G9a in Mammalian Cells. Cancer Res., September 15, 2006; 66(18): 9009 - 9016. [Abstract] [Full Text] [PDF]

				Q.-T. Le, E. Chen, A. Salim, H. Cao, C. S. Kong, R. Whyte, J. Donington, W. Cannon, H. Wakelee, R. Tibshirani, et al. An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non-Small Cell Lung Cancers Clin. Cancer Res., March 1, 2006; 12(5): 1507 - 1514. [Abstract] [Full Text] [PDF]

				R. Cairns, I. Papandreou, and N. Denko Overcoming Physiologic Barriers to Cancer Treatment by Molecularly Targeting the Tumor Microenvironment Mol. Cancer Res., February 1, 2006; 4(2): 61 - 70. [Abstract] [Full Text] [PDF]

				H. K. Dressman, C. Hans, A. Bild, J. A. Olson, E. Rosen, P. K. Marcom, V. B. Liotcheva, E. L. Jones, Z. Vujaskovic, J. Marks, et al. Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy Clin. Cancer Res., February 1, 2006; 12(3): 819 - 826. [Abstract] [Full Text] [PDF]

				D. E. Feldman, V. Chauhan, and A. C. Koong The Unfolded Protein Response: A Novel Component of the Hypoxic Stress Response in Tumors Mol. Cancer Res., November 1, 2005; 3(11): 597 - 605. [Abstract] [Full Text] [PDF]

				D. W. Nelson, H. Cao, Y. Zhu, B. Sunar-Reeder, C. Y.H. Choi, J. D. Faix, J. M. Brown, A. C. Koong, A. J. Giaccia, and Q.-T. Le A Noninvasive Approach for Assessing Tumor Hypoxia in Xenografts: Developing a Urinary Marker for Hypoxia Cancer Res., July 15, 2005; 65(14): 6151 - 6158. [Abstract] [Full Text] [PDF]

				G.-F. von Tempelhoff, L. Heilmann, K. Pollow, and G. Hommel Monitoring of Rheologic Variables During Postoperative High-Dose Brachytherapy for Uterine Cancer Clinical and Applied Thrombosis/Hemostasis, July 1, 2004; 10(3): 239 - 248. [Abstract] [PDF]

				K. Maseide, R. A. Kandel, R. S. Bell, C. N. Catton, B. O'Sullivan, J. S. Wunder, M. Pintilie, D. Hedley, and R. P. Hill Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma Clin. Cancer Res., July 1, 2004; 10(13): 4464 - 4471. [Abstract] [Full Text] [PDF]

				R. A. Cairns and R. P. Hill Acute Hypoxia Enhances Spontaneous Lymph Node Metastasis in an Orthotopic Murine Model of Human Cervical Carcinoma Cancer Res., March 15, 2004; 64(6): 2054 - 2061. [Abstract] [Full Text] [PDF]

				D. Hedley, M. Pintilie, J. Woo, T. Nicklee, A. Morrison, D. Birle, A. Fyles, M. Milosevic, and R. Hill Up-Regulation of the Redox Mediators Thioredoxin and Apurinic/Apyrimidinic Excision (APE)/Ref-1 in Hypoxic Microregions of Invasive Cervical Carcinomas, Mapped Using Multispectral, Wide-Field Fluorescence Image Analysis Am. J. Pathol., February 1, 2004; 164(2): 557 - 565. [Abstract] [Full Text] [PDF]

				D. Hedley, M. Pintilie, J. Woo, A. Morrison, D. Birle, A. Fyles, M. Milosevic, and R. Hill Carbonic Anhydrase IX Expression, Hypoxia, and Prognosis in Patients with Uterine Cervical Carcinomas Clin. Cancer Res., November 15, 2003; 9(15): 5666 - 5674. [Abstract] [Full Text] [PDF]

				Y. Azuma, S.-C. Chou, R. A. Lininger, B. J. Murphy, M. A. Varia, and J. A. Raleigh Hypoxia and Differentiation in Squamous Cell Carcinomas of the Uterine Cervix: Pimonidazole and Involucrin Clin. Cancer Res., October 15, 2003; 9(13): 4944 - 4952. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, J. P. Kirkpatrick, S. A. Snyder, G. Broadwater, F. Farrell, L. Jolliffe, D. M. Brizel, and M. W. Dewhirst Human Recombinant Erythropoietin Significantly Improves Tumor Oxygenation Independent of Its Effects on Hemoglobin Cancer Res., October 1, 2003; 63(19): 6162 - 6165. [Abstract] [Full Text] [PDF]

				R. W. Tsang, S. Juvet, M. Pintilie, R. P. Hill, C. S. Wong, M. Milosevic, W. Chapman, and A. W. Fyles Pretreatment Proliferation Parameters Do Not Add Predictive Power to Clinical Factors in Cervical Cancer Treated with Definitive Radiation Therapy Clin. Cancer Res., October 1, 2003; 9(12): 4387 - 4395. [Abstract] [Full Text] [PDF]

				B. Bachtiary, M. Schindl, R. Potter, B. Dreier, T. H. Knocke, J. A. Hainfellner, R. Horvat, and P. Birner Overexpression of Hypoxia-inducible Factor 1{alpha} Indicates Diminished Response to Radiotherapy and Unfavorable Prognosis in Patients Receiving Radical Radiotherapy for Cervical Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2234 - 2240. [Abstract] [Full Text] [PDF]

				J. H. A. M. Kaanders, K. I. E. M. Wijffels, H. A. M. Marres, A. S. E. Ljungkvist, L. A. M. Pop, F. J. A. van den Hoogen, P. C. M. de Wilde, J. Bussink, J. A. Raleigh, and A. J. van der Kogel Pimonidazole Binding and Tumor Vascularity Predict for Treatment Outcome in Head and Neck Cancer Cancer Res., December 1, 2002; 62(23): 7066 - 7074. [Abstract] [Full Text] [PDF]

				C. N. Coleman, J. B. Mitchell, and K. Camphausen Tumor Hypoxia: Chicken, Egg, or a Piece of the Farm? J. Clin. Oncol., February 1, 2002; 20(3): 610 - 615. [Full Text] [PDF]